Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer.

Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer. - PRIMUS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48348

Enrollment

Registered

2020-01-13

Start date

2020-02-20

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Expression of PD-(L)-1 prostate cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Local relapse of prostate cancer, who is candidate for a salvage HDR treatment. - 18 years or older - Willing and able to comply with the study prescriptions. - Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion criteria

Exclusion criteria: - Not eligible for proposed (HDR brachytherapy) treatment. - No compliance

Design outcomes

Primary

Measure	Time frame
Primary endpoint: expression of PD-(L)-1 in the tumor.	—

Secondary

Measure	Time frame
Secondary endpoints: presence of CXCL12, IL-23 receptor in the tumor at 4 different time points (before and after the 1st fraction; before the 2nd and 3rd fraction of the salvage treatment). Furthermore, increase of T cell infiltration, and HLA class I-A,B,C expressive lymphocytes will be detected.	—

Countries

Netherlands

Outcome results